mepolizumab + reslizumab + benralizumab

**Mepolizumab + reslizumab + benralizumab** is a hypothetical combination of three anti-interleukin-5 (IL-5) pathway monoclonal antibodies: **mepolizumab** (humanized IgG1 anti-IL-5), **reslizumab** (humanized IgG4 anti-IL-5), and **benralizumab** (humanized afucosylated IgG1 anti-IL-5 receptor alpha). Each individually targets eosinophil maturation, activation, and survival to treat **severe eosinophilic asthma** by depleting eosinophils via distinct mechanisms—mepolizumab and reslizumab bind soluble IL-5 to prevent receptor engagement, while benralizumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) against eosinophils and precursors. No clinical data exists for this specific triple combination, which is not approved or studied; dual combinations like mepolizumab + dupilumab or benralizumab + dupilumab have been explored off-label for refractory severe asthma with mixed type 2 inflammation.[1][3][7] Developers include **GSK** (mepolizumab, brand **Nucala**), **Teva** (reslizumab, brand **Cinqair**), and **AstraZeneca** (benralizumab, brand **Fasenra**).[2][3][6][9]